Prediabetes Market Projected to Hit USD 85486.8 Million by 2032, Expanding at 11 % CAGR: Credence Research

Market Outlook

The global prediabetes market is set for strong expansion as rising obesity, sedentary lifestyles, and aging populations continue to push screening and early-stage intervention rates higher. The market reached USD 37,095 million in 2024 and is projected to climb to USD 85,486.8 million by 2032, driven by wider adoption of HbA1c testing, digital health platforms, and risk-stratification tools. Government programs that promote early detection and lifestyle change support broader demand across hospitals, clinics, and home-based care. Growing awareness about diabetes prevention also drives steady uptake of nutrition programs, continuous glucose monitoring tools, and personalized disease-management services.
New product launches and partnerships between diagnostics firms, digital health companies, and insurers continue to shape the competitive landscape. Major stakeholders focus on behavior-change platforms, AI-enabled risk prediction, and remote monitoring to improve long-term outcomes for high-risk populations. Many countries are investing in preventive care, which encourages wider reimbursement for screening and digital coaching programs. This shift from treatment to prevention is expected to accelerate adoption of scalable technology solutions, placing the market on a strong growth path through 2032.

Key Growth Drivers

Rising global diabetes risk is a major force driving growth in the prediabetes market. Higher rates of obesity, unhealthy diets, and limited physical activity have sharply increased the number of individuals at risk, pushing governments and healthcare systems to invest in early detection. Wider screening using HbA1c and fasting plasma glucose tests has helped identify more patients in the early stages. Strong public health campaigns and education programs also raise awareness, which supports faster adoption of preventive care solutions across clinics and home-based platforms.
Technology integration is another key growth engine. Digital coaching apps, wearable glucose monitors, and AI-enabled risk-prediction tools allow early intervention and continuous engagement. These tools support better patient outcomes by helping users track lifestyle changes, monitor glucose trends, and receive real-time guidance. Partnerships between device makers, digital health firms, and insurers have improved accessibility and reimbursement for prevention programs. This shift toward personalized, tech-enabled care is expected to drive sustained demand in the prediabetes market.

Tailor the report to align with your specific business needs and gain targeted insights. Request - https://www.credenceresearch.com/report/prediabetes-market


Regional Analysis

North America holds the leading share in the prediabetes market due to high screening rates, strong awareness programs, and broad access to digital health tools. Europe follows with steady growth supported by national prevention strategies and rising adoption of remote monitoring platforms. Asia Pacific shows the fastest expansion as large populations, rapid urbanization, and increasing obesity levels drive wider diagnostic uptake. Latin America continues to improve early detection through government-led campaigns, while the Middle East & Africa benefit from expanding healthcare infrastructure and rising investment in preventive diabetes care.

Key Player Analysis

• AstraZeneca
• GlaxoSmithKline
• Takeda Pharmaceutical Company
• Novo Nordisk
• Abbott Laboratories
• Boehringer Ingelheim
• Novartis AG
• Amgen Inc.
• Pfizer Inc.
• Astellas Pharma

Tailor the report to align with your specific business needs and gain targeted insights. Request - https://www.credenceresearch.com/report/prediabetes-market


Segments

By Drug Class:
• Biguanides
• Thiazolidinediones
• Alpha-glucosidase inhibitors
• GLP-1 receptor agonists
• DPP-4 inhibitors
• Nutraceuticals
By Age Group:
• Adolescents
• Young adults
• Middle-aged adults
• Elderly adults
By Type:
• Impaired fasting glucose (IFG)
• Impaired glucose tolerance (IGT)
• Combined IFG and IGT
By Administration:
• Oral
• Injectable
• Digital therapeutics
By Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Tailor the report to align with your specific business needs and gain targeted insights. Request - https://www.credenceresearch.com/report/prediabetes-market

Credence Research Europe LTD
128 City Road, London,
EC1V 2NX, UNITED KINGDOM
Europe - +44 7809 866 263
North America - +1 304 308 1216
Australia - +61 4192 46279
Asia Pacific - +81 5050 50 9250
+64 22 017 0275
India - +91 6232 49 3207
sales@credenceresearch.com
www.credenceresearch.com

Credence Research is a viable intelligence and market research platform that provides quantitative B2B research to more than 2000 clients worldwide and is built on the Give principle. The company is a market research and consulting firm serving governments, non-legislative associations, non-profit organizations, and various organizations worldwide. We help our clients improve their execution in a lasting way and understand their most imperative objectives.

This release was published on openPR.